Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05935007 · ClinicalTrials.gov registry record
Aveir DR Real-World Evidence Post-Approval Study
A clinical trial of Bradycardia and Arrythmia, sponsored by Abbott Medical Devices.
- Recruiting
- Registry status
- 1,805
- Enrollment target
- 1
- Study location
NCT05935007: Recruiting study of Bradycardia and Arrythmia, sponsored by Abbott Medical Devices.
NCT05935007 is a study of Bradycardia and Arrythmia that is actively recruiting participants, run by Abbott Medical Devices. The registered enrollment target is 1,805 participants, below the 4,350-participant average among 29 other Bradycardia trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05935007, a study of Bradycardia and Arrythmia, is actively recruiting participants, sponsored by Abbott Medical Devices.
- RECRUITING
- Registry status
- 1,805 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this post-approval study is to evaluate the long-term safety of the dual-chamber Aveir DR leadless pacemaker using real-world evidence methods.
Primary Outcome
Freedom from key acute complications through 30 days post implant procedure
Conditions Studied
Interventions
- DEVICE Aveir DR Leadless Pacemaker System
Study Locations (1)
California
- Abbott - Sylmar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,805 participants |
| Start Date | 2023-10-31 |
| Est. Completion | 2030-01 |
What NCT05935007 shows while recruiting
NCT05935007 is an observational study that tracks outcomes without assigning an intervention. Its 1,805 participants enrollment target places it among the larger protocols in the corpus, below the 4,350-participant average among 29 other Bradycardia trials with a reported enrollment target (59% lower).
The record links to 3 conditions, with Bradycardia appearing as the primary indexed condition, and to 1 intervention - of which Aveir DR Leadless Pacemaker System is the first listed.
NCT05935007 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05935007 about?
NCT05935007 is a clinical study titled "Aveir DR Real-World Evidence Post-Approval Study". The purpose of this post-approval study is to evaluate the long-term safety of the dual-chamber Aveir DR leadless pacemaker using real-world evidence methods.
What is the current status of trial NCT05935007?
This trial is currently recruiting. The enrollment target is 1,805 participants. The study started on 2023-10-31. Estimated completion is 2030-01.
What conditions does trial NCT05935007 study?
This clinical trial studies the following conditions: Bradycardia, Arrythmia, Cardiac Pacemaker.
What interventions are being tested in trial NCT05935007?
The interventions under investigation include: Aveir DR Leadless Pacemaker System (DEVICE).
Who is sponsoring clinical trial NCT05935007?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05935007 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bradycardia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05935007's enrollment target sits among peer trials
1,805 10th of 29 higher than 20 of 29 other Bradycardia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bradycardia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effect of Womb Recordings on Maturation of Respiratory Control in Preterm Infants
RECRUITING · NA
-
Aveir VR Real-World Evidence Post-Approval Study
RECRUITING
-
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
RECRUITING
-
The Alaska Oculocardiac Reflex Study
RECRUITING
-
His Bundle Pacing in Bradycardia and Heart Failure
RECRUITING
-
Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05897788 · 1,808 participants · NA
Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
- NCT04980794 · 1,800 participants · NA
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI